JP2017536119A5 - - Google Patents

Download PDF

Info

Publication number
JP2017536119A5
JP2017536119A5 JP2017526918A JP2017526918A JP2017536119A5 JP 2017536119 A5 JP2017536119 A5 JP 2017536119A5 JP 2017526918 A JP2017526918 A JP 2017526918A JP 2017526918 A JP2017526918 A JP 2017526918A JP 2017536119 A5 JP2017536119 A5 JP 2017536119A5
Authority
JP
Japan
Prior art keywords
lna
nucleosides
oligonucleotide according
nucleoside
phosphorothioate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017526918A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017536119A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/076967 external-priority patent/WO2016079181A1/en
Publication of JP2017536119A publication Critical patent/JP2017536119A/ja
Publication of JP2017536119A5 publication Critical patent/JP2017536119A5/ja
Pending legal-status Critical Current

Links

JP2017526918A 2014-11-19 2015-11-18 キラルホスホロチオエート連結を含むlnaギャップマーオリゴヌクレオチド Pending JP2017536119A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
EP14193887.8 2014-11-19
EP14193887 2014-11-19
EP14198167.0 2014-12-16
EP14198167 2014-12-16
EP15182401 2015-08-25
EP15182401.8 2015-08-25
EP15191074.2 2015-10-22
EP15191075.9 2015-10-22
EP15191075 2015-10-22
EP15191076 2015-10-22
EP15191074 2015-10-22
EP15191076.7 2015-10-22
PCT/EP2015/076967 WO2016079181A1 (en) 2014-11-19 2015-11-18 Lna gapmer oligonucleotides comprising chiral phosphorothioate linkages

Publications (2)

Publication Number Publication Date
JP2017536119A JP2017536119A (ja) 2017-12-07
JP2017536119A5 true JP2017536119A5 (cg-RX-API-DMAC7.html) 2018-11-15

Family

ID=54608516

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017526905A Pending JP2017536366A (ja) 2014-11-19 2015-11-18 Lnaキラルホスホロチオエート
JP2017526918A Pending JP2017536119A (ja) 2014-11-19 2015-11-18 キラルホスホロチオエート連結を含むlnaギャップマーオリゴヌクレオチド

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017526905A Pending JP2017536366A (ja) 2014-11-19 2015-11-18 Lnaキラルホスホロチオエート

Country Status (4)

Country Link
US (2) US20180112217A1 (cg-RX-API-DMAC7.html)
EP (2) EP3220921A1 (cg-RX-API-DMAC7.html)
JP (2) JP2017536366A (cg-RX-API-DMAC7.html)
WO (2) WO2016079183A1 (cg-RX-API-DMAC7.html)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009323766B2 (en) 2008-12-02 2016-10-06 Wave Life Sciences Ltd. Method for the synthesis of phosphorus atom modified nucleic acids
SG177564A1 (en) 2009-07-06 2012-02-28 Ontorii Inc Novel nucleic acid prodrugs and methods of use thereof
EP2620428B1 (en) 2010-09-24 2019-05-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
US9605019B2 (en) 2011-07-19 2017-03-28 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
JP6246121B2 (ja) 2012-07-13 2017-12-13 株式会社新日本科学 キラル核酸アジュバント
SG10201912895PA (en) 2012-07-13 2020-02-27 Wave Life Sciences Ltd Chiral control
JP6268157B2 (ja) 2012-07-13 2018-01-24 株式会社Wave Life Sciences Japan 不斉補助基
US11162096B2 (en) 2013-10-14 2021-11-02 Ionis Pharmaceuticals, Inc Methods for modulating expression of C9ORF72 antisense transcript
JPWO2015108047A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
EP3095460A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
PT3094728T (pt) 2014-01-16 2022-05-19 Wave Life Sciences Ltd Desenho quiral
WO2016097212A1 (en) 2014-12-17 2016-06-23 Proqr Therapeutics Ii B.V. Targeted rna editing
US10793855B2 (en) * 2015-01-06 2020-10-06 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of C9ORF72 antisense transcript
WO2016167780A1 (en) 2015-04-16 2016-10-20 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of c9orf72 antisense transcript
MA43072A (fr) 2015-07-22 2018-05-30 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
EP3394258B1 (en) * 2015-10-22 2021-09-22 Roche Innovation Center Copenhagen A/S In vitro toxicity screening assay
JP7017517B2 (ja) * 2016-03-18 2022-02-08 ロシュ イノベーション センター コペンハーゲン エーエス アシル保護l-lna-グアノシンモノマー
MA45270A (fr) 2016-05-04 2017-11-09 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
MA45496A (fr) 2016-06-17 2019-04-24 Hoffmann La Roche Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
US11105794B2 (en) * 2016-06-17 2021-08-31 Hoffmann-La Roche Inc. In vitro nephrotoxicity screening assay
JP7012033B2 (ja) * 2016-06-17 2022-02-10 エフ.ホフマン-ラ ロシュ アーゲー インビトロ腎毒性スクリーニングアッセイ
EP3475424A1 (en) 2016-06-22 2019-05-01 ProQR Therapeutics II B.V. Single-stranded rna-editing oligonucleotides
CN110352244B (zh) 2016-09-01 2023-03-21 ProQR治疗上市公司Ⅱ 化学修饰的编辑rna的单链寡核苷酸
EP3539970B1 (en) * 2016-11-14 2021-06-09 Tokyo University of Science Foundation Polymerizable compound, compound, and method for producing boranophosphate oligomer
CN110088113A (zh) * 2016-11-23 2019-08-02 波涛生命科学有限公司 用于亚磷酰胺和寡核苷酸合成的组合物和方法
EP3568479A1 (en) * 2017-01-13 2019-11-20 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides for modulating nfkb1 expression
EP3568481A1 (en) * 2017-01-13 2019-11-20 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides for modulating relb expression
EP3571300A1 (en) 2017-01-19 2019-11-27 ProQR Therapeutics II B.V. Oligonucleotide complexes for use in rna editing
JP2021502059A (ja) 2017-10-13 2021-01-28 ロシュ イノベーション センター コペンハーゲン エーエス 部分的に立体定義されたオリゴヌクレオチドのサブライブラリーを使用することによる、アンチセンスオリゴヌクレオチドの、改良された立体定義されたホスホロチオエートオリゴヌクレオチド変異体を同定するための方法
CR20210262A (es) * 2017-10-16 2022-06-27 Hoffmann La Roche MOLÉCULA DE ÁCIDOS NUCLEICOS PARA LA REDUCCIÓN DEL ARNm DE PAPD5 Y PAPD7 EN EL TRATAMIENTO DE LA INFECCIÓN DE LA HEPATITIS B (DIVISIONAL DEL EXPEDIENTE 2020-0205)
RU2020121752A (ru) 2017-12-01 2021-12-30 ТЕХАССКАЯ УНИВЕРСИТЕТСКАЯ СИСТЕМА А энд М Средство для лечения синдрома ангельмана на основе антисмысловой нуклеиновой кислоты
JP2021508327A (ja) * 2017-12-22 2021-03-04 ロシュ イノベーション センター コペンハーゲン エーエス 新規のチオホスホラミダイト
WO2019122279A1 (en) * 2017-12-22 2019-06-27 Roche Innovation Center Copenhagen A/S Oligonucleotides comprising a phosphorodithioate internucleoside linkage
CN111448317B (zh) * 2017-12-22 2025-07-04 罗氏创新中心哥本哈根有限公司 包含二硫代磷酸酯核苷间键的缺口聚物寡核苷酸
CN111819283A (zh) 2018-01-12 2020-10-23 百时美施贵宝公司 靶向α-突触核蛋白的反义寡核苷酸及其用途
US11447775B2 (en) 2018-01-12 2022-09-20 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof
AU2019252812A1 (en) 2018-04-13 2020-10-01 Bristol-Myers Squibb Company Novel phosphorous (V)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophoshorous (V) compounds
GB201808146D0 (en) 2018-05-18 2018-07-11 Proqr Therapeutics Ii Bv Stereospecific Linkages in RNA Editing Oligonucleotides
SG11202012759XA (en) 2018-07-03 2021-01-28 Hoffmann La Roche Oligonucleotides for modulating tau expression
EP3819378A4 (en) * 2018-07-04 2022-09-14 Aichi Medical University OLIGONUCLEOTIDES FOR CONTROL OF TAU SPLICING AND THEIR USES
MX2021009950A (es) * 2019-02-20 2021-09-21 Roche Innovation Ct Copenhagen As Oligonucleotidos gapmeros de fosfonoacetato.
SG11202112741XA (en) 2019-05-31 2021-12-30 Aligos Therapeutics Inc Modified gapmer oligonucleotides and methods of use
KR20220129023A (ko) 2020-01-16 2022-09-22 브리스톨-마이어스 스큅 컴퍼니 C-p 결합의 모듈식 거울상이성질체발산 합성을 위한 시약 및 그의 용도
KR20250069923A (ko) 2022-09-19 2025-05-20 브리스톨-마이어스 스큅 컴퍼니 신규한 인(v)-기반 시약, 이의 제조 방법, 및 입체-규정 유기인(v) 화합물의 제조에 있어서의 그의 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242589B1 (en) * 1998-07-14 2001-06-05 Isis Pharmaceuticals, Inc. Phosphorothioate oligonucleotides having modified internucleoside linkages
ES2620472T5 (es) * 2006-10-18 2020-07-09 Ionis Pharmaceuticals Inc Compuestos antisentido
SG10201912895PA (en) * 2012-07-13 2020-02-27 Wave Life Sciences Ltd Chiral control
MY177989A (en) * 2013-01-30 2020-09-28 Hoffmann La Roche Lna oligonucleotide carbohydrate conjugates

Similar Documents

Publication Publication Date Title
JP2017536119A5 (cg-RX-API-DMAC7.html)
JP2017536366A5 (cg-RX-API-DMAC7.html)
IL300119A (en) Oligonucleotides for inducing paternal ube3a expression
JP2020058368A5 (cg-RX-API-DMAC7.html)
JP2016116520A5 (cg-RX-API-DMAC7.html)
JP2018512110A5 (cg-RX-API-DMAC7.html)
JP2020022483A5 (cg-RX-API-DMAC7.html)
JP2018512041A5 (cg-RX-API-DMAC7.html)
JP2013226147A5 (cg-RX-API-DMAC7.html)
JP2017505623A5 (cg-RX-API-DMAC7.html)
JP2012510297A5 (cg-RX-API-DMAC7.html)
JP2013511990A5 (cg-RX-API-DMAC7.html)
JP2021505129A5 (cg-RX-API-DMAC7.html)
HRP20210315T1 (hr) Oligonukleotidi za smanjenje ekspresije pd-l1
JP2015514418A5 (cg-RX-API-DMAC7.html)
JP2016530294A5 (cg-RX-API-DMAC7.html)
JP2018530530A5 (cg-RX-API-DMAC7.html)
JP2017093448A5 (cg-RX-API-DMAC7.html)
JP2016171800A5 (cg-RX-API-DMAC7.html)
JP2019503394A5 (cg-RX-API-DMAC7.html)
JP2013535212A5 (cg-RX-API-DMAC7.html)
JP2014511686A5 (cg-RX-API-DMAC7.html)
JP2012105686A5 (cg-RX-API-DMAC7.html)
JP2009532044A5 (cg-RX-API-DMAC7.html)
JP2018525357A5 (cg-RX-API-DMAC7.html)